IP Library Granted Patent US 10,952,894
Granted Patent B2
US 10,952,894 · App. 15/872,206 · Granted Mar 23, 2021

Device for ocular access

Inventors: Amy Lee Hammack (Santa Clara, CA); Stanley R. Conston (San Carlos, CA); Ronald Yamamoto (San Francisco, CA)
Assignee: CLEARSIDE BIOMEDICAL, INC.
A61F9/0017A61F9/00727A61F9/00736A61M5/46A61M5/486A61M2005/3103A61M2210/0612
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,952,894
App. No.
15/872,206
Granted
Mar 23, 2021
Kind
B2
Abstract

The present invention provides devices to access the suprachoroidal space or sub-retinal space in an eye via a minimally invasive transconjunctival approach. The devices may also be used after a partial dissection, for example after dissection of the outer scleral layer of the eye, and using the device within the dissection to access the suprachoroidal space or the sub-retinal space.

Claims (30)

1. A method of administering a therapeutic substance to a subretinal space of an eye via a suprachoroidal space and without piercing a retina of the eye, the method comprising:

creating a pathway from outside the eye to the suprachoroidal space via a dissection of a sclera of the eye;

inserting a distal end of a tubular member into the suprachoroidal space via the pathway;

with at least a portion of the tubular member disposed within the suprachoroidal space, advancing a hollow needle distally through a lumen of the tubular member, piercing the choroid, and into the subretinal space of the eye;

with at least a portion of the tubular member in the suprachoroidal space, conveying a fluidic guard to the subretinal space to provide a forward directed force against the retina; and

with a distal end of the hollow needle disposed within the subretinal space, conveying, via the hollow needle, the therapeutic substance into the subretinal space.

2. The method of claim 1 , further comprising:

viewing, via an imaging system that is external to the eye, the fluidic guard within the subretinal space.

3. The method of claim 1 , wherein the fluidic guard is a liquid that contains sodium.

4. The method of claim 1 , further comprising:

with the tubular member in the suprachoroidal space, conveying a fluidic guard to the subretinal space to displace retinal tissue away from the tubular member.

5. The method of claim 1 , further comprising:

at least one of during or after the inserting the tubular member into the suprachoroidal space, securing at least a portion of the tubular member to the eye.

6. The method of claim 1 , wherein the distal end of the hollow needle includes a non-linear curve such that, during the advancing the hollow needle distally into the subretinal space, a path through which the distal end of the hollow needle pierces the choroid and enters the subretinal space is tangential to a curve of the eye.

7. The method of claim 6 , wherein the non-linear curve is between 10 degrees and 60 degrees.

8. The method of claim 1 , wherein conveying the therapeutic substance includes conveying the therapeutic substance through an opening in the distal end of the hollow needle at an angle offset from a longitudinal axis of a proximal portion of the hollow needle.

9. A method of administering a therapeutic substance to a subretinal space of an eye via a suprachoroidal space and without piercing a retina of the eye, the method comprising:

inserting at least a portion of a tubular member into the suprachoroidal space via a dissection of a sclera of the eye;

with the tubular member disposed within the suprachoroidal space, advancing a hollow needle distally through a lumen of the tubular member, piercing the choroid, and into the subretinal space of the eye;

with the tubular member disposed within the suprachoroidal space, conveying a fluidic guard to the subretinal space to provide a forward directed force against the retina; and

with a distal end of the hollow needle disposed within the subretinal space, conveying, via the hollow needle, the therapeutic substance into the subretinal space.

10. The method of claim 9 , wherein the conveying the fluidic guard to the subretinal space includes displacing retinal tissue away from the tubular member.

11. The method of claim 9 , further comprising:

at least one of during or after the inserting the tubular member into the suprachoroidal space, securing the tubular member to the eye.

12. A method of administering a therapeutic substance to a subretinal space of an eye via a suprachoroidal space and without piercing a retina of the eye, the method comprising:

creating a pathway from outside the eye to the suprachoroidal space via a dissection of a sclera of the eye;

inserting a distal end of a tubular member into the suprachoroidal space via the pathway;

with at least a portion of the tubular member disposed within the suprachoroidal space, advancing a hollow needle distally through a lumen of the tubular member, piercing the choroid, and into the subretinal space of the eye;

with at least a portion of the tubular member in the suprachoroidal space, conveying a fluidic guard to the subretinal space to displace retinal tissue away from the tubular member; and

with a distal end of the hollow needle disposed within the subretinal space, conveying, via the hollow needle, the therapeutic substance into the subretinal space.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Jul 7, 2020
From: SILICON VALLEY BANK
To: CLEARSIDE BIOMEDICAL, INC.
Reel/Frame 053139/0929 →
SECURITY INTEREST Recorded Aug 29, 2019
From: CLEARSIDE BIOMEDICAL, INC.
To: SILICON VALLEY BANK
Reel/Frame 050217/0270 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2018
From: HAMMACK, AMY LEE; CONSTON, STANLEY R.; YAMAMOTO, RONALD
To: ISCIENCE INTERVENTIONAL CORPORATION
Reel/Frame 045066/0110 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2018
From: ISCI HOLDINGS INC. F/K/A/ ISCIENCE INTERVENTIONAL CORPORATION
To: CLEARSIDE BIOMEDICAL, INC.
Reel/Frame 045066/0115 →
CHANGE OF NAME Recorded Feb 28, 2018
From: ISCIENCE INTERVENTIONAL CORPORATION
To: ISCI HOLDINGS INC.
Reel/Frame 046289/0744 →